Genprex Files S-1 Registration Statement

Ticker: GNPX · Form: S-1 · Filed: May 14, 2025 · CIK: 1595248

Sentiment: neutral

Topics: s-1, registration-statement, pharmaceuticals

TL;DR

Genprex filed an S-1, looks like they're raising capital soon.

AI Summary

Genprex, Inc. filed an S-1 registration statement on May 14, 2025, to register securities under the Securities Act of 1933. The company, headquartered in Austin, TX, is in the pharmaceutical preparations industry. Ryan M. Confer serves as President, CEO, and CFO.

Why It Matters

This S-1 filing indicates Genprex, Inc. is preparing to offer new securities to the public, which could impact its capital structure and stock availability.

Risk Assessment

Risk Level: medium — S-1 filings are often associated with potential stock dilution or new offerings, which can introduce volatility.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1 filing for Genprex, Inc.?

The S-1 filing is a registration statement under the Securities Act of 1933, indicating Genprex, Inc. is preparing to offer securities to the public.

Who is the principal executive officer of Genprex, Inc. mentioned in the filing?

Ryan M. Confer is listed as the President, Chief Executive Officer, and Chief Financial Officer of Genprex, Inc.

What is Genprex, Inc.'s primary business classification?

Genprex, Inc. is classified under Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.

Where are Genprex, Inc.'s principal executive offices located?

The principal executive offices of Genprex, Inc. are located at 3300 Bee Cave Road #650-227, Austin, TX 78746.

When was this S-1 registration statement filed with the SEC?

This S-1 registration statement was filed with the Securities and Exchange Commission on May 14, 2025.

Filing Details

This Form S-1 (Form S-1) was filed with the SEC on May 14, 2025 by Ryan M. Confer regarding Genprex, Inc. (GNPX).

View full filing on EDGAR

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing